Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7831.

https://doi.org/10.1182/blood-2024-204150

Published: 2024

Journal Articles

Real-World Treatment Patterns and Outcomes of Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (BiTE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) at the Yale Cancer Center Network (YCCN)

Poy Theprungsirikul, Rong Wang, Man-Yee Merl, Shi-Yi Wang, Natalia Neparidze

Blood (2024) 144 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2024-201603

Published: 2024

Journal Articles

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Terri L. Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J. Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius Girnius, Patrick Hagen, Emma C. Scott, Antje Hoering, Brian G.M. Durie, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2024-208341

Published: 2024

Journal Articles

A Mixed Methods Study to Describe the Relationship between Burden of Illness, Social Needs, and Identity Experiences Among Patients with Multiple Myeloma

Natalia Neparidze, Amandeep Godara, Dee Lin, Hoa H. Le, Karen Fixler, Lisa Shea, Stephanie Everson, Christine Brittle, Kimberly Brunisholz

Blood (2023) 142 (Supplement 1): 7353.

https://doi.org/10.1182/blood-2023-178893

Published: 2023

Journal Articles

Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma

Sabrina L. Browning, Allison J. Li, Terri L. Parker, Noffar Bar, Tara Anderson, Erica Stevens, Yuxin Liu, Martin Matthews, Jennifer VanOudenhove, Rebecca Cardone, Qiushi Sun, Robert Hale, Stephanie Halene, Richard Kibbey, Natalia Neparidze

Blood (2023) 142 (Supplement 1): 4774.

https://doi.org/10.1182/blood-2023-186401

Published: 2023

Journal Articles

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Tariq Kewan, Sayeef Mirza, Alexander B Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean X Gu, Yuxin Liu, Jennifer Vanoudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2023) 142 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2023-187295

Published: 2023

Journal Articles

Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders

Sean X Gu, Patrick G Gallagher, Ayesha Butt, Vivian W Gu, Kimberly Lezon-Geyda, Vincent P Schulz, Stephanie Prozora, Alfred I Lee, Natalia Neparidze, Noffar Bar, Kelsey Martin, Jennifer Cornell, Giavanna Chirico, Raja Chakraborty, Henry M Rinder, John Hwa, Robert D Bona

Blood (2023) 142 (Supplement 1): 1197.

https://doi.org/10.1182/blood-2023-177946

Published: 2023

Journal Articles

Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study

Poy Theprungsirikul, Yuxin Liu, Natalia Neparidze

Blood (2023) 142 (Supplement 1): 7364.

https://doi.org/10.1182/blood-2023-186985

Published: 2023

Journal Articles

Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib

Jessica M. Stempel, Rong Wang, Rory Michael Shallis, Scott F. Huntington, Amer M. Zeidan, Natalia Neparidze, Mengyang Di, Xiaomei Ma, Nikolai A. Podoltsev

Blood (2022) 140 (Supplement 1): 11004–11006.

https://doi.org/10.1182/blood-2022-165156

Published: 2022

Journal Articles

Racial Difference in Part D Enrollment and Survival Among Older Patients with Multiple Myeloma

Rong Wang, Natalia Neparidze, Xiaomei Ma, Graham A Colditz, Su-Hsin Chang, Shi-Yi Wang

Blood (2022) 140 (Supplement 1): 5270–5271.

https://doi.org/10.1182/blood-2022-164741

Published: 2022

Journal Articles

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Wilson I. Gonsalves, Natalia Neparidze, Jacob B. Allred, Shaji K Kumar, Joel M. Reid, Geoffrey Shapiro, Brian A. Costello, Richard Piekarz, Rachid C. Baz, Srinivas Devarakonda

Blood (2022) 140 (Supplement 1): 7315–7316.

https://doi.org/10.1182/blood-2022-164966

Published: 2022

Journal Articles

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Abu-Sayeef Mirza, Alexander Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer VanOudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2022) 140 (Supplement 1): 10410–10412.

https://doi.org/10.1182/blood-2022-168374

Published: 2022

Journal Articles

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Blood (2022) 140 (Supplement 1): 7086–7087.

https://doi.org/10.1182/blood-2022-168109

Published: 2022

Journal Articles

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7308–7310.

https://doi.org/10.1182/blood-2022-166325

Published: 2022

Journal Articles

Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis

Mengyang Di, Can Cui, Shalin K. Kothari, Amer M. Zeidan, Nikolai Podoltsev, Natalia Neparidze, Rory M. Shallis, Rong Wang, Xiaomei Ma, Scott F. Huntington

Blood (2021) 138 (Supplement 1): 182.

https://doi.org/10.1182/blood-2021-146417

Published: 2021

Journal Articles

Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States

Natalia Neparidze, Krystal W. Lau, Xiaoliang Wang, Amy J. Davidoff, Scott F. Huntington, Omer Hassan Jamy, Gregory Calip, Harsh Shah, Deborah M. Stephens, Rebecca A. Miksad, Ravi Parikh, Samuel Takvorian, Gaurav Goyal, Erlene K Seymour

Blood (2021) 138 (Supplement 1): 1973.

https://doi.org/10.1182/blood-2021-153787

Published: 2021

Journal Articles

Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period

Natalia Neparidze, Rong Wang, Amer M. Zeidan, Nikolai Podoltsev, Rory M. Shallis, Xiaomei Ma, Amy J. Davidoff, Scott F. Huntington

Blood (2021) 138 (Supplement 1): 4092.

https://doi.org/10.1182/blood-2021-148998

Published: 2021

Journal Articles

Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database

Gregory S Calip, Mustafa S Ascha, Xiaoliang Wang, Amy E Pierre, Kathleen Maignan, Niquelle B Wadé, Siyang Leng, Erlene K Seymour, Brian C-H Chiu, Karen Sweiss, Pritesh R Patel, Natalia Neparidze

Blood (2021) 138 (Supplement 1): 4121.

https://doi.org/10.1182/blood-2021-152774

Published: 2021

Journal Articles

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Talib Dosani, Anna Poteraj, Terri L. Parker, Noffar Bar, Sabrina L. Browning, Elan Gorshein, Tara Anderson, Karl Insogna, Natalia Neparidze

Blood (2021) 138 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2021-147466

Published: 2021

Journal Articles

Iron Infusion Reactions: Risk Factors and Real-World Experience

Ayesha Butt, Tinatin Muradashvili, Sara Soliman, George Goshua, Adrienne Joy Burns, Noffar Bar, Kelsey Martin, Gena Borgman, Robert D. Bona, Alfred Ian Lee, Natalia Neparidze

Blood (2021) 138 (Supplement 1): 4154.

https://doi.org/10.1182/blood-2021-151048

Published: 2021

NARROW

Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma

Real-World Treatment Patterns and Outcomes of Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (BiTE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) at the Yale Cancer Center Network (YCCN)

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

A Mixed Methods Study to Describe the Relationship between Burden of Illness, Social Needs, and Identity Experiences Among Patients with Multiple Myeloma

Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders

Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study

Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib

Racial Difference in Part D Enrollment and Survival Among Older Patients with Multiple Myeloma

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis

Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States

Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period

Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Iron Infusion Reactions: Risk Factors and Real-World Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only